Bone
metastases is a common form of cancer of the skeleton that inhabits in
bone marrow and stimulates the local bone activity. In this condition, the
normal bone homeostasis disrupts which leads to the development of the tumour.
Some of the major symptoms observed in patients with bone metastases are bone
pain, spinal cord compression, and high blood calcium levels.
Bone metastases can be diagnosed by various types of imaging
tests such as X-Ray, bone scan, positron emission tomography (PET), magnetic
resonance imaging (MRI), and computed tomography (CT) scan, blood tests, urine
tests, and bone biopsy. ChemoCentryx, Inc. is in the process of developing
CCX354 as a CCR1 receptor antagonist for the treatment of bone metastases.
Moreover, Amgen Inc. is developing denosumab as a RANKL ligand inhibitor for
the treatment of this medical condition. Pfizer Inc., and Eli Lilly and Company
are also key players having drugs for bone metastases in their pipeline.
Request to Get the Sample Pages at:
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
No comments:
Post a Comment